Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion
Principal Investigator
Jamie Kennedy, MD (ucsf)
Photo of Jamie Kennedy
Jamie Kennedy

Description

Summary

Evaluate the performance of the CorBand product when used to monitor patients.

Details

The goal of the study is to demonstrate the validity and reliability of the CorBand across a suite of six clinical measures by comparing the measurements to similar outputs of FDA cleared devices:

  • CorBand heart rate and heart rate variability will be compared to an electrocardiogram.
  • CorBand bioimpedance will be compared to recorded extracted fluid and a bioimpedance measurement device.
  • CorBand respiration rate will be compared to an respiratory rate sensor.
  • CorBand skin temperature will be compared to a skin temperature monitoring device.
  • CorBand activity will be compared to an activity monitor.
  • CorBand outputs will be compared to the outputs of the CardioMEMS system.

Device safety, comfort, and ease-of-use will also be evaluated as part of this study. Adverse events and serious adverse events will be documented throughout the study duration.

Keywords

Heart Failure Chronic Kidney Diseases Hemodialysis Kidney Diseases Renal Insufficiency, Chronic CorBand Activity Monitor Bioimpedance spectrometer ECG respiratory rate sensor

Eligibility

For people ages 18 years and up

INCLUSION:

Arm 1:

  1. Subject is ≥ 18 years of age (legal age to give informed consent).
  2. Subject is NYHA class I, II, III, or IV or undergoing cardiac management at the time of enrollment.
  3. Willing and capable of participating in all study visits and complying with medication/treatment requirements associated with this clinical study at an approved clinical study center.

Arm 2:

  1. Subject is ≥ 18 years of age (legal age to give informed consent).
  2. Subject receives chronic hemodialysis.
  3. Subject undergoes at least two hemodialysis sessions per week.
  4. Willing and capable of participating in all study visits and comply with medication/treatment requirements associated with this clinical study at an approved clinical study center.

Arm 3:

  1. Subject is ≥ 18 years of age (legal age to give informed consent).
  2. Subject is implanted with the CardioMEMS HF device.
  3. Subject is NYHA class I, II, III, or IV or undergoing cardiac management at the time of enrollment.
  4. Willing and capable of participating in all study visits and complying with medication/treatment requirements associated with this clinical study at an approved clinical study center.

Arm 4:

  1. Subject is ≥ 18 years of age (legal age to give informed consent).
  2. Subject is NYHA class I, II, III, or IV or undergoing cardiac management at the time of enrollment.
  3. Subject is stabilized during (and not yet discharged from) a hospitalization for exacerbation of symptomatic heart failure or a clinic visit for symptomatic heart failure associated with unscheduled treatment with IV diuretics.
  4. Willing and capable of participating in all study visits and complying with medication/treatment requirements associated with this clinical study at an approved clinical study center.

EXCLUSION:

  1. The subject is unable or refuses to sign the informed consent.
  2. Subject is pregnant or planning to become pregnant during the study.
  3. A life expectancy of less than 6 months per clinician discretion.
  4. Subject has an implanted pacemaker or pacing device (Arm 1 and Arm 2 only).
  5. Poor healthcare literacy that would prevent the subjects from using the CorBand and/or completing questionnaires.
  6. Physical or mental impairment preventing use of the CorBand or compliance with study requirements.
  7. Material sensitivity to wearable devices, including the CorBand device.

Additional Exclusion Criteria for Arm 4 Only:

  1. Home use of intravenous continuous inotropes or planned outpatient weekly inotrope infusions.
  2. Subject has been implanted with a ventricular assist device.
  3. . Subject is listed on heart transplant list.
  4. . Subject has a glomerular filtration rate (GFR) less than 30 mL/min.
  5. . Subject has uncontrolled hypertension defined as 160/100 mmHg on two consecutive readings taken 15 min apart after subject has been resting for 15 min.
  6. . Subject is undergoing or expected to undergo chronic hemodialysis (regularly scheduled sessions unrelated to a worsening heart failure event) during the study.
  7. . Subject is incompatible with CorBand (e.g., skin type resulting in poor data measurements).

Locations

  • University of California, San Francisco
    San Francisco California 94143 United States
  • Satellite Healthcare
    San Jose California 95128 United States

Lead Scientist at UC Health

  • Jamie Kennedy, MD (ucsf)
    My clinical interests are heart failure, mechanical circulatory support, heart transplantation, pulmonary hypertension, and critical care cardiology. I direct the cardiac intensive care service at UCSF.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
ReThink Medical
ID
NCT03993886
Study Type
Interventional
Last Updated